Canada markets closed

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.3400-0.0600 (-4.29%)
At close: 04:00PM EDT
1.5000 +0.16 (+11.94%)
After hours: 05:39PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.4000
Open1.3800
Bid1.3400 x 1300
Ask1.6000 x 800
Day's Range1.3400 - 1.4300
52 Week Range1.2900 - 5.6860
Volume105,533
Avg. Volume243,815
Market Cap59.233M
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    InflaRx to Present at the H.C. Wainwright Global Investment Conference

    JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwright Global Investment Conference. The hybrid conference will be held in person in Miami, Florida and virtually from May 23rd to May 26th. InflaRx will present in person on Wednesday, May 25th at 10:30 AM EDT /

  • GlobeNewswire

    InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update

    Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underwayFinal data from Phase IIa open-label study in patients with pyoderma gangrenosum presented at 2022 AAD Annual Meeting; end-of-Phase II meeting with FDA scheduled for mid-2022In Phase II trial in cutaneous squamous cell carcinoma, second dosing cohort of combination arm started; enrollment

  • GlobeNewswire

    InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

    Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary endpointPre-specified sensitivity analysis of the primary endpoint results in p-values of <0.05 in three out of four planned analyses in favor of vilobelimab treatment43% relative reduction in 28-day all-cause mortality detected in pre-specified subgroup analysis in Western European patients comparin